

# Luigi Pirtoli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8635082/publications.pdf>

Version: 2024-02-01

32  
papers

872  
citations

623734

14  
h-index

501196

28  
g-index

32  
all docs

32  
docs citations

32  
times ranked

4039  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ability of Delta Radiomics to Predict a Complete Pathological Response in Patients with Loco-Regional Rectal Cancer Addressed to Neoadjuvant Chemo-Radiation and Surgery. <i>Cancers</i> , 2022, 14, 3004.	3.7	13
2	Post-operative management of brain metastases: GRADE-based clinical practice recommendations on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 793-802.	2.5	0
3	Aromatase Inhibitorsâ€™ Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5625.	4.1	49
4	Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1270.	4.1	9
5	Delta-radiomics increases multicentre reproducibility: a phantom study. <i>Medical Oncology</i> , 2020, 37, 38.	2.5	54
6	Radiomics predicts survival of patients with advanced nonâ€™small cell lung cancer undergoing PDâ€™1 blockade using Nivolumab. <i>Oncology Letters</i> , 2020, 19, 1559-1566.	1.8	46
7	On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1712-1719.	2.8	0
8	Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?. <i>Clinical Neurology and Neurosurgery</i> , 2019, 184, 105445.	1.4	3
9	Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. <i>Journal of Neuro-Oncology</i> , 2019, 143, 447-455.	2.9	6
10	Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-8.	1.5	36
11	Could PD-1/PDL1 immune checkpoints be linked to HLA signature?. <i>Immunotherapy</i> , 2019, 11, 1523-1526.	2.0	15
12	Evaluation of long term survival in pretreated metastatic colorectal cancer patients undergoing GOLFIG chemoimmunotherapy regimen.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15057-e15057.	1.6	0
13	Perilesional edema in brain cancer: Independent prognosticator or epiphenomenon of biomolecular signature?. <i>Radiotherapy and Oncology</i> , 2018, 129, 183-184.	0.6	1
14	Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide. <i>World Neurosurgery</i> , 2018, 109, e662-e668.	1.3	9
15	How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies. <i>Frontiers in Immunology</i> , 2018, 9, 2941.	4.8	20
16	Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 462-472.	0.8	35
17	Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy. <i>BioMed Research International</i> , 2017, 2017, 1-7.	1.9	9
18	The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma. <i>Clinical Neurology and Neurosurgery</i> , 2016, 149, 15-21.	1.4	16

#	ARTICLE	IF	CITATIONS
19	Bone structure texture analysis as a potential tool to estimate radiation induced insufficiency fracture risk. <i>Radiotherapy and Oncology</i> , 2016, 120, 184.	0.6	5
20	In Regard to Kubicek etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 923-924.	0.8	1
21	Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 427-435.	1.6	203
22	Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients. <i>Oncolmmunology</i> , 2016, 5, e1101205.	4.6	24
23	Combined Epidermal Growth Factor Receptor and Beclin1 Autophagic Protein Expression Analysis Identifies Different Clinical Presentations, Responses to Chemo- and Radiotherapy, and Prognosis in Glioblastoma. <i>BioMed Research International</i> , 2015, 2015, 1-13.	1.9	18
24	Epidermal Growth Factor Receptor Expression May Correlate with Survival Through Clinical and Radiological Features of Aggressiveness in Glioblastoma Treated with Radiochemotherapy. <i>Anticancer Research</i> , 2015, 35, 4117-24.	1.1	8
25	Lymphatic Vascularization in Prostate Adenocarcinoma: Correlation with Tumor Grade, Androgen Withdrawal and Prognosis. <i>Anticancer Research</i> , 2015, 35, 5595-600.	1.1	8
26	Clinical radiobiology of glioblastoma multiforme. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 925-932.	2.0	45
27	Phase Ib study of TSPP (thymidilate synthaseÂpoly-epitope peptide) vaccine in combination with GOLFIG chemoimmuno-burst in advanced colon cancer patients: Results from the TSPP/VAC-1/c trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13098-e13098.	1.6	0
28	Patterns of Care and Survival in a Retrospective Analysis of 1059 Patients With Glioblastoma Multiforme Treated Between 2002 and 2007. <i>Neurosurgery</i> , 2010, 67, 446-458.	1.1	73
29	Three-Dimensional Conformal Radiotherapy, Temozolomide Chemotherapy, and High-Dose Fractionated Stereotactic Boost in a Protocol-Driven, Postoperative Treatment Schedule for High-Grade Gliomas. <i>Tumori</i> , 2009, 95, 329-337.	1.1	7
30	The prognostic role of Beclin 1 protein expression in high-grade gliomas. <i>Autophagy</i> , 2009, 5, 930-936.	9.1	134
31	Three-dimensional conformal radiotherapy, temozolomide chemotherapy, and high-dose fractionated stereotactic boost in a protocol-driven, postoperative treatment schedule for high-grade gliomas. <i>Tumori</i> , 2009, 95, 329-37.	1.1	2
32	Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 788-799.	0.8	23